Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease

Nilsson, Johanna ; Gobom, Johan ; Sjödin, Simon ; Brinkmalm, Gunnar ; Ashton, Nicholas J ; Svensson, Johan ; Johansson, Per LU ; Portelius, Erik ; Zetterberg, Henrik and Blennow, Kaj , et al. (2021) In Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring 13(1).
Abstract

Introduction: Synaptic dysfunction and degeneration is one of the earliest events in Alzheimer's disease (AD) and the best correlate of cognitive decline. Thus, identification and validation of biomarkers reflecting synaptic degeneration to be used as prognostic biomarkers are greatly needed.

Method: Solid-phase extraction and parallel reaction monitoring mass spectrometry were used to quantify 17 synaptic proteins in CSF, in two cross-sectional studies including AD (n = 52) and controls (n = 37).

Results: Increased concentrations of beta-synuclein, gamma-synuclein, neurogranin, phosphatidylethanolamine-binding protein 1, and 14-3-3 proteins were observed in AD patients compared to controls, while neuronal pentraxin-2 and... (More)

Introduction: Synaptic dysfunction and degeneration is one of the earliest events in Alzheimer's disease (AD) and the best correlate of cognitive decline. Thus, identification and validation of biomarkers reflecting synaptic degeneration to be used as prognostic biomarkers are greatly needed.

Method: Solid-phase extraction and parallel reaction monitoring mass spectrometry were used to quantify 17 synaptic proteins in CSF, in two cross-sectional studies including AD (n = 52) and controls (n = 37).

Results: Increased concentrations of beta-synuclein, gamma-synuclein, neurogranin, phosphatidylethanolamine-binding protein 1, and 14-3-3 proteins were observed in AD patients compared to controls, while neuronal pentraxin-2 and neuronal pentraxin receptor were decreased.

Discussion: We have established a method with a novel panel of synaptic proteins as biomarkers of synaptic dysfunction. The results indicate that several of the proteins included in the panel may serve as synaptic biomarkers for AD.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer, Synaptic dysfunction, CSF BIOMARKERS
in
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
volume
13
issue
1
article number
e12179
publisher
Elsevier
external identifiers
  • pmid:33969172
  • scopus:85108226937
ISSN
2352-8729
DOI
10.1002/dad2.12179
language
English
LU publication?
yes
id
0f62e05b-3f66-4c1e-ba2b-2d7bed0c3132
date added to LUP
2021-05-12 10:20:21
date last changed
2024-06-15 11:07:27
@article{0f62e05b-3f66-4c1e-ba2b-2d7bed0c3132,
  abstract     = {{<p>Introduction: Synaptic dysfunction and degeneration is one of the earliest events in Alzheimer's disease (AD) and the best correlate of cognitive decline. Thus, identification and validation of biomarkers reflecting synaptic degeneration to be used as prognostic biomarkers are greatly needed.</p><p>Method: Solid-phase extraction and parallel reaction monitoring mass spectrometry were used to quantify 17 synaptic proteins in CSF, in two cross-sectional studies including AD (n = 52) and controls (n = 37).</p><p>Results: Increased concentrations of beta-synuclein, gamma-synuclein, neurogranin, phosphatidylethanolamine-binding protein 1, and 14-3-3 proteins were observed in AD patients compared to controls, while neuronal pentraxin-2 and neuronal pentraxin receptor were decreased.</p><p>Discussion: We have established a method with a novel panel of synaptic proteins as biomarkers of synaptic dysfunction. The results indicate that several of the proteins included in the panel may serve as synaptic biomarkers for AD.</p>}},
  author       = {{Nilsson, Johanna and Gobom, Johan and Sjödin, Simon and Brinkmalm, Gunnar and Ashton, Nicholas J and Svensson, Johan and Johansson, Per and Portelius, Erik and Zetterberg, Henrik and Blennow, Kaj and Brinkmalm, Ann}},
  issn         = {{2352-8729}},
  keywords     = {{Alzheimer; Synaptic dysfunction; CSF BIOMARKERS}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Elsevier}},
  series       = {{Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring}},
  title        = {{Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease}},
  url          = {{http://dx.doi.org/10.1002/dad2.12179}},
  doi          = {{10.1002/dad2.12179}},
  volume       = {{13}},
  year         = {{2021}},
}